Natera Inc (NASDAQ:NTRA) CEO Matthew Rabinowitz Sells 251,699 Shares

Share on StockTwits

Natera Inc (NASDAQ:NTRA) CEO Matthew Rabinowitz sold 251,699 shares of the stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $24.17, for a total transaction of $6,083,564.83. Following the completion of the sale, the chief executive officer now owns 1,443,558 shares of the company’s stock, valued at approximately $34,890,796.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Matthew Rabinowitz also recently made the following trade(s):

  • On Monday, September 24th, Matthew Rabinowitz sold 35,845 shares of Natera stock. The stock was sold at an average price of $23.98, for a total transaction of $859,563.10.
  • On Wednesday, September 26th, Matthew Rabinowitz sold 324,844 shares of Natera stock. The stock was sold at an average price of $24.85, for a total transaction of $8,072,373.40.
  • On Friday, September 21st, Matthew Rabinowitz sold 212,001 shares of Natera stock. The stock was sold at an average price of $23.88, for a total transaction of $5,062,583.88.
  • On Tuesday, September 11th, Matthew Rabinowitz sold 185,163 shares of Natera stock. The stock was sold at an average price of $25.13, for a total transaction of $4,653,146.19.
  • On Thursday, September 13th, Matthew Rabinowitz sold 403,462 shares of Natera stock. The shares were sold at an average price of $24.90, for a total transaction of $10,046,203.80.

NTRA traded up $0.66 during trading on Friday, reaching $20.77. 461,912 shares of the company’s stock were exchanged, compared to its average volume of 422,908. The company has a debt-to-equity ratio of -3.32, a quick ratio of 1.56 and a current ratio of 1.69. Natera Inc has a fifty-two week low of $8.60 and a fifty-two week high of $29.62. The firm has a market capitalization of $1.46 billion, a PE ratio of -8.65 and a beta of 2.24.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, August 8th. The medical research company reported ($0.55) EPS for the quarter, hitting analysts’ consensus estimates of ($0.55). The firm had revenue of $63.07 million during the quarter, compared to analyst estimates of $61.71 million. Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.55) EPS. Equities analysts forecast that Natera Inc will post -2.07 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of NTRA. Sofinnova Ventures Inc bought a new stake in Natera during the 1st quarter worth about $28,742,000. Fred Alger Management Inc. bought a new stake in Natera during the 2nd quarter worth about $33,271,000. Millennium Management LLC lifted its position in Natera by 135.5% during the 2nd quarter. Millennium Management LLC now owns 744,598 shares of the medical research company’s stock worth $14,013,000 after buying an additional 428,376 shares in the last quarter. BlackRock Inc. lifted its position in Natera by 19.4% during the 2nd quarter. BlackRock Inc. now owns 2,086,829 shares of the medical research company’s stock worth $39,274,000 after buying an additional 338,766 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Natera by 35.2% during the 2nd quarter. Renaissance Technologies LLC now owns 792,400 shares of the medical research company’s stock worth $14,913,000 after buying an additional 206,471 shares in the last quarter. 66.31% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have recently issued reports on the stock. Piper Jaffray Companies lifted their target price on shares of Natera to $27.00 and gave the company an “overweight” rating in a research note on Thursday, August 9th. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Saturday. BidaskClub lowered shares of Natera from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 30th. TheStreet raised shares of Natera from a “d” rating to a “c-” rating in a report on Thursday, August 9th. Finally, Craig Hallum set a $23.00 price target on shares of Natera and gave the company a “positive” rating in a report on Thursday, June 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $26.00.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Story: What is a put option?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.